LEAP THERAPEUTICS, INC. (LPTX) financial statements (2021 and earlier)

Company profile

Business Address 47 THORNDIKE STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments41626
Cash and cash equivalents41626
Business combination, contingent consideration, asset0  
Other undisclosed current assets012
Total current assets:41728
Noncurrent Assets
Property, plant and equipment000
Deposits noncurrent assets1  
Other noncurrent assets 21
Deferred tax assets, net00
Other undisclosed noncurrent assets2  
Total noncurrent assets:321
TOTAL ASSETS:71929
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities866
Accounts payable543
Accrued liabilities333
Other undisclosed current liabilities0  
Total current liabilities:866
Noncurrent Liabilities
Liabilities, other than long-term debt0  
Financial instruments subject to mandatory redemption, settlement terms, share value, amount0  
Other undisclosed noncurrent liabilities1312
Total noncurrent liabilities:1312
Total liabilities:91018
Stockholders' equity
Stockholders' equity attributable to parent(2)911
Common stock000
Additional paid in capital193162142
Accumulated other comprehensive income (loss)00(0)
Accumulated deficit(195)(154)(130)
Total stockholders' equity:(2)911
TOTAL LIABILITIES AND EQUITY:71929

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Operating expenses(33)(31)(32)
Operating loss:(33)(31)(32)
Nonoperating income (expense)0(1)1
Foreign currency transaction gain (loss), before tax0(1)1
Interest and debt expense(0)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(33)(32)(32)
Other undisclosed income from continuing operations before income taxes082
Loss from continuing operations before income taxes:(33)(23)(30)
Income tax expense (benefit)0(0)0
Net loss attributable to parent:(33)(23)(30)
Preferred stock dividends and other adjustments(0) (0)
Net loss available to common stockholders, basic:(33)(23)(30)
Other undisclosed net loss available to common stockholders, diluted (7)(0)
Net loss available to common stockholders, diluted:(33)(30)(30)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(33)(23)(30)
Comprehensive loss:(33)(23)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)1(1)
Comprehensive loss, net of tax, attributable to parent:(33)(23)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: